Verinurad

Verinurad
Clinical data
Other names	RDEA-3170; RDEA3170
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-[3-(4-Cyanonaphthalen-1-yl)pyridin-4-yl]sulfanyl-2-methylpropanoic acid;
CAS Number	1352792-74-5 ;
PubChem CID	54767229 ;
IUPHAR/BPS	9327 ;
DrugBank	DB11873 ;
UNII	12WJ62D047 ;
KEGG	D11129 ;
ChEMBL	ChEMBL3707347 ;
Chemical and physical data
Formula	C20H16N2O2S
Molar mass	348.42 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N;
	InChI InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24); Key:YYBOLPLTQDKXPM-UHFFFAOYSA-N;

Last updated January 02, 2026

Verinurad is a selective URAT1 inhibitor developed for gout and heart failure by AstraZeneca.^[1]^[2]^[3]

References

↑ Johansson, Susanne; Han, David; Hunt, Thomas; Björck, Karin; Florica, Delia; Gillen, Michael; Hall, Jesse; Erlandsson, Fredrik (June 2022). "Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants". Pharmacology Research & Perspectives. 10 (3): e00929. doi:10.1002/prp2.929. PMC 9121888 . PMID 35593744.
↑ Fitz-Patrick, David; Roberson, Kent; Niwa, Kiyoshi; Fujimura, Takabumi; Mori, Koji; Hall, Jesse; Yan, Xiaohong; Shen, Zancong; Liu, Sha; Ito, Yasushi; Baumgartner, Scott (2 November 2019). "Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials". Modern Rheumatology. 29 (6): 1042–1052. doi: 10.1080/14397595.2018.1538003 . PMID 30334639. S2CID 52988677.
↑ Tan, Philip K.; Liu, Sha; Gunic, Esmir; Miner, Jeffrey N. (6 April 2017). "Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout". Scientific Reports. 7 (1): 665. Bibcode:2017NatSR...7..665T. doi:10.1038/s41598-017-00706-7. ISSN 2045-2322. PMC 5429603 . PMID 28386072.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Johansson, Susanne; Han, David; Hunt, Thomas; Björck, Karin; Florica, Delia; Gillen, Michael; Hall, Jesse; Erlandsson, Fredrik (June 2022). "Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants". Pharmacology Research & Perspectives. 10 (3): e00929. doi:10.1002/prp2.929. PMC 9121888 . PMID 35593744.

[2] Fitz-Patrick, David; Roberson, Kent; Niwa, Kiyoshi; Fujimura, Takabumi; Mori, Koji; Hall, Jesse; Yan, Xiaohong; Shen, Zancong; Liu, Sha; Ito, Yasushi; Baumgartner, Scott (2 November 2019). "Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials". Modern Rheumatology. 29 (6): 1042–1052. doi: 10.1080/14397595.2018.1538003 . PMID 30334639. S2CID 52988677.

[3] Tan, Philip K.; Liu, Sha; Gunic, Esmir; Miner, Jeffrey N. (6 April 2017). "Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout". Scientific Reports. 7 (1): 665. Bibcode:2017NatSR...7..665T. doi:10.1038/s41598-017-00706-7. ISSN 2045-2322. PMC 5429603 . PMID 28386072.

[1]

[2]

[3]